Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429566 | 1.00 | TRPC5 (0.39) | TRPC5ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL16492254 | 0.95 | TRPC5 (0.41) | TRPC5ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL21073879 | 0.94 | TRPC5 (0.45) | TRPC5ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL21385635 | 0.94 | TRPC5 (0.41) | TRPC5ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL14027738 | 0.94 | TRPC5 (0.41) | TRPC5ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL14007669 | 0.93 | TRPC5 (0.37) | TRPC5ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL18735566 | 0.92 | MCHR1 (0.34) | TRPC5ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL4856873 | 0.91 | LMNA (0.40) | TRPC5ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL16340050 | 0.91 | TRPC5 (0.37) | TRPC5ALDH1A1KMT2AMEN1MAPK1 | |
| SCHEMBL4856850 | 0.90 | TRPC5 (0.40) | TRPC5ALDH1A1KMT2AMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | claimed |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | Janssen Biopharma, Inc. (US) | 2022-11-17 | — | — | US | claimed |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-10-13 | — | — | US | claimed |
| CN-114716426-A | Antiviral compounds | 詹森生物制药有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | claimed |
| EP-3687543-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | claimed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | claimed |
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | claimed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | claimed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | claimed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | claimed |
| US-20120148678-A1 | SUSTAINED RELEASE OF POORLY WATER SOLUBLE ACTIVE COMPOUNDS | ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC. (US) | 2012-06-14 | — | — | US | claimed |
| WO-2012078815-A1 | SUSTAINED RELEASE IMPLANTS CONTAINING A BIODEGRADABLE POLYMER, CYCLODEXTRIN AND POORLY WATER SOLUBLE ACTIVE COMPOUNDS | ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC (US) | 2012-06-14 | — | — | WO | claimed |
| EP-2257809-B1 | METHOD FOR IDENTIFYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN | TIBOTEC PHARM LTD (IE) | 2012-02-08 | — | — | EP | claimed |
| US-20110009408-A1 | METHODS FOR IDENTIFIYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN | JANSSEN SCIENCES IRELAND UC (IE) | 2011-01-13 | — | — | US | claimed |
| EP-2257809-A1 | METHOD FOR IDENTIFYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN | Tibotec Pharmaceuticals (IE) | 2010-12-08 | — | — | EP | claimed |
| WO-2009106580-A1 | METHOD FOR IDENTIFYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN | TIBOTEC PHARMACEUTICALS (IE) | 2009-09-03 | — | — | WO | claimed |
| US-7449463-B2 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-11-11 | — | — | US | claimed |
| EP-1697345-B1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2008-03-12 | — | — | EP | claimed |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | JANSSEN SCIENCES IRELAND UC (IE) | 2007-02-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | TRPC5 4438/4885ALDH1A1 4011/4885KMT2A 4241/4885 |
| US-20110009408-A1 | METHODS FOR IDENTIFIYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN | STXBP1, DBI, MAVS | TRPC5 4863/4885ALDH1A1 2720/4885KMT2A 4269/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | TRPC5 4094/4885ALDH1A1 3562/4885KMT2A 3794/4885 |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | TRPC5 4438/4885ALDH1A1 4011/4885KMT2A 4241/4885 |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-3 | TRPC5 3474/4885ALDH1A1 3915/4885KMT2A 159/4885 |
| US-10358453-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | TRPC5 4438/4885ALDH1A1 4011/4885KMT2A 4241/4885 |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | TRPC5 4094/4885ALDH1A1 3562/4885KMT2A 3794/4885 |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | TRPC5 4438/4885ALDH1A1 4011/4885KMT2A 4241/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | TRPC5 2887/4885ALDH1A1 4172/4885KMT2A 3282/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | TRPC5 4094/4885ALDH1A1 3562/4885KMT2A 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.